eISSN: 1897-4309
ISSN: 1428-2526
Contemporary Oncology/Współczesna Onkologia
Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
7/2007
vol. 11
 
Share:
Share:
abstract:

Autologous stem cell transplantation (ASCT) as a consolidation of remission in peripheral T-cell lymphoma (PTCL) – the preliminary results of the first 11 patients

Beata Stella-Hołowiecka
,
Agata Wieczorkiewicz
,
Grzegorz Helbig
,
Grażyna Bober
,
Maria Wojciechowska
,
Jacek Najda
,
Lucja Kachel
,
Jerzy Hołowiecki

Współczesna Onkologia (2007) vol. 11; 7 (376–380)
Online publish date: 2007/10/02
View full text Get citation
 
Background: Peripheral T-cell lymphomas show aggressive course and poor outcome. High-dose chemotherapy is thought to improve outcome in these patients, but the role of up-front ASCT is still unclear. Material and methods: 11 patients (5 male/6 female); median age at ASCT was 41 years. The CHOP regimen was administered as an induction treatment. The median number of chemotherapy regimens needed to achieve CR or PR was 8 (range 3-20). 7 patients (64%) achieved complete remission before ASCT; 4 showed PR. The conditioning regimen was CBV for 10 patients and 1 patient received BEAM. Results: The median number of mononuclear cells was 3.5 × 108/kg (range 2.02-6.9); median CD34+ cell dose infused/kg was 6.2 × 106/kg (range 1.1-17.2). Engraftment of neutrophils >0.5 × 109/l was observed at a median of 14 days (range 12-18), engraftment of platelets >50 × 109/l was achieved in a median of 16 (range 10-30). The 100-day mortality rate was 0%. 4 out of 11 patients (36%) developed progression/relapse after ASCT after a median of 7 months (range 4-9). 3 out of 4 patients died in disease progression, 1 patient underwent allogeneic stem cell transplantation. Only 1 out of 7 patients transplanted in CR had an early relapse occurring 4 months after ASCT. With a median of 20 months (range 6-52) of follow-up 6 patients (55%) remain in CR. The estimated probability of 3-year overall survival (OS) and progression-free survival (PFS) is 60% and 62% respectively. Conclusions: Up-front ASCT in PTCL is highly effective, but further study with a large post-transplant population are needed to confirm the results.
keywords:

peripheral T-cell lymphoma, consolidation of remission, autologous stem cell transplantation

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.